Potential of Synthetic and Natural Compounds as Novel Histone Deacetylase Inhibitors for the Treatment of Hematological Malignancies
Cancers · 17.05.2023 · 15 (10) · 2808
DOI: 10.3390/cancers15102808 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cancers, online erschienen am 17.05.2023. Verfasst von Dilipkumar Pal und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Sciences, Guru Ghasidas Vishwavidyalaya (A Central University), Bilaspur 495 009, India. Die Arbeit wurde bisher 27-mal zitiert (Crossref) und nennt 138 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS.
Abstract (Originalsprache)
Histone deacetylases (HDACs) and histone acetyltransferases (HATs) are enzymes that remove or add acetyl groups to lysine residues of histones, respectively. Histone deacetylation causes DNA to more snugly encircle histones and decreases gene expression, whereas acetylation has the opposite effect. Through these small alterations in chemical structure, HATs and HDACs regulate DNA expression. Recent research indicates histone deacetylase inhibitors (HDACis) may be used to treat malignancies, including leukemia, B-cell lymphoma, virus-associated tumors, and multiple myeloma. These data suggest that HDACis may boost the production of immune-related molecules, resulting in the growth of CD8-positive T-cells and the recognition of nonreactive tumor cells by the immune system, thereby diminishing tumor immunity. The argument for employing epigenetic drugs in the treatment of acute myeloid leukemia (AML) patients is supported by evidence that both epigenetic changes and mutations in the epigenetic machinery contribute to AML etiology. Although hypomethylating drugs have been licensed for use in AML, additional epigenetic inhibitors, such as HDACis, are now being tested in humans. Preclinical studies evaluating the efficacy of HDACis against AML have shown the ability of specific agents, such as anobinostat, vorinostat, and tricostatin A, to induce growth arrest, apoptosis, autophagy and cell death. However, these inhibitors do not seem to be successful as monotherapies, but instead achieve results when used in conjunction with other medications. In this article, we discuss the mounting evidence that HDACis promote extensive histone acetylation, as well as substantial increases in reactive oxygen species and DNA damage in hematological malignant cells. We also evaluate the potential of various natural product-based HDACis as therapeutic agents to combat hematological malignancies.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Pharmaceutical Sciences, Guru Ghasidas Vishwavidyalaya (A Central University), Bilaspur 495 009, India.
- Department of Biotechnology, Indian Council for Medical Research-National Institute of Virology, Mumbai 400 012, India.
- Department of Cancer Biology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
- Aurobindo Pharma, Durham, NC 27703, USA.
- Department of Pharmaceutical Chemistry, M.R. College of Pharmaceutical Sciences and Research, Balisha 743 234, India.
- Associate Laboratory in Chemical Engineering, Polytechnic Institute of Leiria, Morro do Lena, Alto do Vieiro, 2411-901 Leiria, Portugal.
ORCID-Profile: Dilipkumar Pal, Arijit Mondal, Ricardo Lagoa, Jack T Burcher, Anupam Bishayee
Förderung
- NCI NIH HHS
Zitieren
APA
Pal, D., Raj, K., Nandi, S. S., Sinha, S., Mishra, A., Mondal, A., Lagoa, R., Burcher, J. T., & Bishayee, A. (2023). Potential of Synthetic and Natural Compounds as Novel Histone Deacetylase Inhibitors for the Treatment of Hematological Malignancies. Cancers, 15(10), 2808. https://doi.org/10.3390/cancers15102808
Vancouver
Pal D, Raj K, Nandi SS, Sinha S, Mishra A, Mondal A, et al. Potential of Synthetic and Natural Compounds as Novel Histone Deacetylase Inhibitors for the Treatment of Hematological Malignancies. Cancers. 2023;15(10):2808. doi:10.3390/cancers15102808
BibTeX
@article{Pal2023,
author = {Pal, Dilipkumar and Raj, Khushboo and Nandi, Shyam Sundar and Sinha, Surajit and Mishra, Abhishek and Mondal, Arijit and Lagoa, Ricardo and Burcher, Jack T and Bishayee, Anupam},
title = {Potential of Synthetic and Natural Compounds as Novel Histone Deacetylase Inhibitors for the Treatment of Hematological Malignancies},
journal = {Cancers},
year = {2023},
volume = {15},
number = {10},
pages = {2808},
doi = {10.3390/cancers15102808}
}
EUVIMED